Amgen Inc (AMGN)

165.45
4.26 2.51
NASDAQ : Health Care
Prev Close 169.71
Open 170.39
Day Low/High 165.33 / 170.39
52 Wk Low/High 130.09 / 181.81
Volume 3.79M
Avg Volume 2.80M
Exchange NASDAQ
Shares Outstanding 748.36M
Market Cap 128.44B
EPS 9.20
P/E Ratio 15.48
Div & Yield 4.00 (2.30%)

Latest News

Four Stellar Stocks to Beat the Biotech Slump

Four Stellar Stocks to Beat the Biotech Slump

Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum

Closing Bell: Wells Fargo Considers Clawbacks; U.S. Stocks Climb

Closing Bell: Wells Fargo Considers Clawbacks; U.S. Stocks Climb

U.S. stocks climbed and the Dow Jones Industrial Average jumped more than 100 points thanks to gains in the tech and consumer sectors.

Stocks Hold at Highs After Clinton-Trump Debate, Oil Tumbles

Stocks Hold at Highs After Clinton-Trump Debate, Oil Tumbles

Stocks add to gains in a relief rally Tuesday following the the first of three presidential debates on Monday.

Amgen (AMGN) Stock Slides, RBC: Clarion Trial May Have Failed Due to Design

Amgen (AMGN) Stock Slides, RBC: Clarion Trial May Have Failed Due to Design

Amgen announced today (AMGN) that its Phase III trial for Kyprolis, a plasma cell cancer drug, produced results that were not statistically significant.

Stocks Climb in Post-Debate Relief Rally, Crude Oil Sinks

Stocks Climb in Post-Debate Relief Rally, Crude Oil Sinks

Stocks move higher in a relief rally Tuesday following the the first of three presidential debates on Monday.

Stock Futures Creep Higher After Clinton-Trump Debate, Crude Falls

Stock Futures Creep Higher After Clinton-Trump Debate, Crude Falls

Stock futures creep higher on Tuesday following the first of three presidential debates, though a drop in crude oil caps gains.

Amgen Multiple Myeloma Drug Kyprolis Fails to Help Newly Diagnosed Patients

Amgen Multiple Myeloma Drug Kyprolis Fails to Help Newly Diagnosed Patients

Amgen's effort to improve disappointing sales of its multiple myeloma drug Kyprolis took a hit Tuesday with the failure of a phase III clinical trial involving newly diagnosed patients.

Amgen Opens Nomination Process For LabCentral Residency

Amgen Opens Nomination Process For LabCentral Residency

Opportunity for Life Sciences and Biotech Startups to Submit Proposal to Win Golden Ticket

Wall Street Sells Off on Worries Over Clinton-Trump Showdown

Wall Street Sells Off on Worries Over Clinton-Trump Showdown

Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.

Biotech ETFs May Be a Prescription for Investment Success, Especially if Trump Becomes President

Biotech ETFs May Be a Prescription for Investment Success, Especially if Trump Becomes President

Driving sector performance are a recent series of mergers and acquisitions, including Horizon Pharma's purchase of Raptor Pharmaceutical Corp. Then there's the political boost...

Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies

Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.

Stocks Fall as Health Care Slumps Ahead of Presidential Debate

Stocks Fall as Health Care Slumps Ahead of Presidential Debate

Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.

FDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases

FDA Approves Amgen's AMJEVITA™ (Adalimumab-Atto) For Treatment Of Seven Inflammatory Diseases

First Regulatory Approval for Company's Biosimilar Portfolio

Will Amgen (AMGN) Stock Be Helped By FDA Approval of Humira Biosimilar?

Will Amgen (AMGN) Stock Be Helped By FDA Approval of Humira Biosimilar?

The FDA approved Amgen's (AMGN) generic version of AbbVie's (ABBV) Humira drug.

New Setback for Sanofi's Lantus Increases Need for M&A

New Setback for Sanofi's Lantus Increases Need for M&A

UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.

Those Wheels Keep Spinning

There are other things to consider besides central banks.

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

First Study to Demonstrate That Lowering LDL Cholesterol With a PCSK9 Inhibitor Impacts Underlying Atherosclerotic Disease on top of Optimized Statin Therapy

Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis

Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis

FRAME Data Simultaneously Published in New England Journal of Medicine and Presented at ASBMR Showed Treatment With Romosozumab Significantly Reduced New Vertebral and Clinical Fractures Through 12 Months

Gilead: Horse of a Different, uh, Color

Gilead: Horse of a Different, uh, Color

The once-mighty biotech has fallen, but entry opportunities will surface.

Spectrum Pharma, FDA and the Buried Truth About a Bladder Cancer Drug Meeting

Spectrum Pharma, FDA and the Buried Truth About a Bladder Cancer Drug Meeting

The FDA told Spectrum not to seek approval for its bladder cancer drug. Spectrum filed anyway but never told investors about the FDA warning.

Amgen Receives Positive CHMP Opinion For Parsabiv™ (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adult Patients With Chronic Kidney Disease On Hemodialysis

Amgen Receives Positive CHMP Opinion For Parsabiv™ (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism In Adult Patients With Chronic Kidney Disease On Hemodialysis

Novel Treatment Administered Intravenously Would put Delivery of Important Therapy in the Hands of the Healthcare Provider

Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine

Amgen Presents Positive Data At EHMTIC 2016 Demonstrating Erenumab Significantly Reduces Monthly Migraine Days In Patients With Chronic Migraine

Significantly Greater Proportion of Patients on Erenumab Experienced a 50 Percent or More Reduction in Number of Migraine Days Compared to Placebo

Amgen To Webcast Investor Call

Amgen To Webcast Investor Call

Amgen (AMGN) Stock Is Wednesday's 'Chart of the Day'

Amgen (AMGN) Stock Is Wednesday's 'Chart of the Day'

Amgen's (AMGN) last run to highs stalled out, but the stock could still push through the old highs, according to TheStreet's Chris Versace and Bob Lang.

Is Amgen the Cure for the Market Blues?

Is Amgen the Cure for the Market Blues?

The shares have some power and legs to get up and through old highs.

Chart of the Week: Amgen

AMGN has some power and legs to get up and through its old highs.